Ketamine Clinical Trials
Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department
To see complete record on clinicaltrials.gov, please visit this link
Id: NCT04260607
Organisation Name: Naval Medical Center Camp Lejeune
Overal Status: Enrolling by invitation
Start Date: January 14, 2020
Last Update: March 2, 2021
Lead Sponsor: Naval Medical Center Camp Lejeune
Brief Summary: Current treatment for acutely suicidal patients are limited to hospitalization, psychotherapy, electro-convulsant therapy, or a combination of the aforementioned. However, this has added to the national boarding problem. Long term pharmacologic treatment for suicidal behaviors and mood stabilization has been studied in specific populations. In these populations, the decreases in suicidal ideation results from stabilization of the underlying psychiatric illness. Ketamine is most commonly used as an anesthetic with analgesic properties. It has been used off-label for pain management, procedural sedation, status epilepticus, and treatment resistant depression. It has been safely administered intravenously and well tolerated for chronic Post Traumatic Stress Disorder. It increases norepinephrine, dopamine, and serotonin through adrenergic neuron stimulation and prevention of catecholamine uptake. There is a strong corollary between stress and the development of depression and suicidal behaviors. It is proposed that the use of low dose intravenous ketamine may have benefit on the suicidal ideation of patients presenting to the Emergency Department.
Conditions:
- Suicide
- Suicide Threat
- Depression Severe
Total execution time in seconds: 0.19571304321289